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ABSTR ACT: In recent years, there has been a proliferation in the development of targeted radionuclide cancer therapy. It is now possible to 
use baseline clinical and imaging assessments to determine the most effective therapy and to tailor this therapy during the course of treatment 
based on radiation dosimetry and tumor response. Although this personalized approach to medicine has the advantage of maximizing therapeutic 
effect while limiting toxicity, it can be challenging to implement and expensive. Further, in order to use targeted radionuclide therapy effectively, 
there is a need for multidisciplinary awareness, education, and collaboration across the scientific, industrial, and medical communities. Even more 
important, there is a growing understanding that combining radiopharmaceuticals with conventional treatment such as chemotherapy and external 
beam radiotherapy may limit patient morbidity while improving survival. Developments in radiopharmaceuticals as biomarkers capable of predict-
ing therapeutic response and targeting disease are playing a central role in medical research. Adoption of a practical approach to manufacturing 
and delivering radiopharmaceuticals, assessing patient eligibility, optimizing post-therapy follow-up, and addressing reimbursement issues will be 
essential for their success.
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Introduction
Targeted radionuclide therapy (TRT), the use of one or more 
radionuclides for targeted therapy at the cellular or molecular 
level, has been around for many years. The first application in 
oncology was in the 1940s when physicians began imaging 
and treating patients with thyroid disease using radioactive 
iodine.1 Radioimmunotherapy (RIT), the use of a radio-
labeled monoclonal antibody for targeted therapy, is more 
recent than TRT, although this is also more than 30 years 
old.2 In 2002, 90Y-ibritumomab tiuxetan (Zevalin; Spectrum 
Pharmaceuticals, Inc.), a radiolabeled anti-CD20 monoclonal 
antibody, was the first RIT to receive Food and Drug Admin-
istration approval for the treatment of patients with relapsed 
or refractory low-grade, follicular, or transformed B-cell non-
Hodgkin lymphoma (NHL).3 This was followed in 2003 by 
131I-tositumomab (Bexxar; GlaxoSmithKline, Inc.), which is 
also a radiolabeled anti-CD20 monoclonal antibody for the 
treatment of patients with NHL.4 Radioactive iodine therapy, 
Zevalin, and Bexxar have been, arguably, the most commonly 
used TRT and RITs throughout the history of clinical nuclear 
medicine.
Recently, interest in the medical community for TRT 
and RIT has been growing. The mechanism of cell death fol-
lowing TRT exposure can result both from a direct radiation 
effect and from crossfire and bystander effects.5 There are sev-
eral commonly used targeted radionuclide therapeutic agents 
(such as 131I and 90Y), and the choice of radionuclide depends 
on the tumor characteristics. For example, radionuclides that 
emit high-energy alpha or beta particles are preferred for the 
treatment of bulky tumors, although radionuclides that emit 
Auger electrons are considered to be beneficial for the eradi-
cation of small clusters of cancer cells or small tumors. Most 
radionuclides are metals, and care must be taken to choose an 
appropriate chelating agent tailored to the TRT application 
and radionuclide being used.6 The mechanism of cell death 
following RIT is two pronged: (1) apoptosis due to radia-
tion exposure and (2) the effect of the host immune response 
against target cells, including induction of apoptosis through 
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direct signal transduction, complement-mediated cytotoxicity, 
and antibody-mediated cellular cytotoxicity.7
One of the most appealing benefits of TRT and RIT is 
the possibility for personalized medical care, optimized for 
patient and disease characteristics. Unlike conventional sys-
temic chemotherapy, TRT and RIT allow radiation to be 
delivered directly to the targeted site of disease with potentially 
less toxicity from exposure of normal tissues. There are several 
considerations that must be kept in mind while designing a 
personalized treatment plan for patients. Namely, treatment 
decisions should be informed using a combination of clini-
cal findings and biomarkers/imaging to assess baseline disease 
extent, likelihood of response to a given radiopharmaceutical, 
and to calculate the optimal amount of radioactivity needed 
for maximal therapy with minimal or manageable toxicity. In 
order to choose the appropriate TRT or RIT and estimate 
the amount of radioactivity to be given, pretherapy treatment 
planning may be needed. This would likely require additional 
patient visits, imaging, and potentially interventional proce-
dures, which can be challenging both for the treating physi-
cian and for the patient to arrange and perform.8
In 2013 and 2014, the Society of Nuclear Medicine and 
Molecular Imaging and the National Cancer Institute part-
nered to host two joint workshops on TRT, bringing together 
members from the scientific, clinical, and industrial com-
munities to review what had been learned about TRT and to 
explore the approach needed to bring advances into medical 
practice.6,9 The current increase in baseline imaging to iden-
tify disease sites, predict response to therapy, and determine 
the specific treatment needed to achieve optimal results was 
discussed. The advantage of evaluating the effect of therapy 
both clinically and with imaging and then using these results 
to modify treatment for maximal patient benefit was reviewed. 
It was agreed that for TRT to be widely adopted, several chal-
lenges would have to be overcome and close collaboration 
between members of the medical team, the scientific commu-
nity, and industry would be key.6,9 
Current Applications
Today, TRT and RIT are encountered daily in many nuclear 
medicine clinics, typically for the treatment of patients with 
thyroid cancer, metastatic prostate cancer, and lymphoma.
Thyroid cancer is the most common endocrine malig-
nancy with an estimated 62,450 new cases and 1,950 deaths 
in 2015.10 Radioactive iodine therapy is commonly used for 
the treatment of well-differentiated thyroid cancer. Although 
generally well tolerated, there are both short- and long-term 
complications of using radioiodine treatment. Early compli-
cations may include thyroiditis, gastrointestinal symptoms, 
sialadenitis/xerostomia, dry eyes, and bone marrow suppres-
sion while late complications may include pulmonary fibrosis, 
secondary cancers, and permanent bone marrow suppression 
among others.11 In recent years, the indications, efficacy, and 
amount of activity given have been debated. Advocates for a 
personalized approach to TRT in patients with thyroid cancer 
promote the need for selective administration of radioactive 
iodine and use of lower amounts of radioactivity to minimize 
toxicity whenever possible.12 According to the American 
Thyroid Association, thyroid cancer patients are classified 
as low risk when there is no macroscopic disease following 
surgery, no metastases, vascular invasion, or aggressive histol-
ogy. Intermediate-risk patients may have microscopic tumor 
invasion into the soft tissue adjacent to the thyroid gland, 
lymph node spread, vascular invasion, or radioactive iodine 
uptake outside the thyroid gland on a radioactive iodine scan. 
High-risk patients have macroscopic tumor invasion, distant 
metastases, and potentially high thyroglobulin levels out of 
proportion with the postradioactive iodine therapy scan. 
Although adjuvant radioactive iodine therapy is not recom-
mended for low-risk patients, it is recommended for high-risk 
and for most intermediate-risk patients.13 Indeed, a recent 
review of over 21,000 patients treated for intermediate-risk 
papillary thyroid cancer showed that the addition of adjuvant 
radioactive iodine therapy resulted in a reduction in the risk of 
death by approximately 30%.14 High-dose radioiodine ther-
apy is also helpful for advanced disease at presentation, local 
recurrence that is not amenable to surgery alone, and distant 
metastatic disease.15
Prostate cancer is the most commonly diagnosed malig-
nancy in men with an estimated 220,800 new cases and 
27,540 deaths in 2015.16 TRT has been used for the palliation 
of bone pain from metastatic prostate cancer for several years; 
however, radium-223 dichloride (Xofigo; Bayer Healthcare 
Pharmaceuticals) was the first approved alpha-emitting radio-
pharmaceutical and the first TRT shown to extend life in men 
with castration-resistant disease.17 In the last 3 years, Xofigo 
has become increasingly ubiquitous in routine oncologic clini-
cal practice. Although shown to increase overall survival and 
delay the time to first skeletal related event, there are adverse 
reactions, including gastrointestinal symptoms, peripheral 
edema, and bone marrow suppression. Most complications are 
short-term with long-term complications such as bone mar-
row failure being uncommon.18 The incidence of secondary 
malignancies is unknown.
Unlike TRT, RIT using antibodies or antibody frag-
ments to target tumor cells is uncommonly encountered in the 
nuclear medicine clinic today. Rituximab is a chimeric IgG1 
anti-CD20 monoclonal antibody that is used in combination 
with chemotherapy in the treatment of patients with lym-
phoma. The idea of RIT stems from the belief that adding 
a radioisotope to an anti-CD20 monoclonal antibody would 
augment effectiveness by enabling targeted radiation therapy. 
In general, radioisotope conjugation is thought to improve 
efficacy, although patients have shown impressive responses 
using the nonradiolabeled antibody as well. Zevalin (ibritu-
momab tiuxetan) is a monoclonal mouse IgG1 anti-CD20 
antibody in conjunction with the chelator tiuxetan, to which a 
radioactive isotope (90Y) is added for the purposes of targeted 
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radiation therapy. It is the most commonly used RIT and has 
been available for over 15 years for the treatment of relapsed 
or refractory low-grade follicular lymphoma or transformed 
B-cell NHL, including rituximab-refractory follicular NHL. 
Zevalin can improve progression-free survival and is associ-
ated with improved overall response rate in advanced follicular 
lymphoma compared with using rituximab alone.19–21 In addi-
tion, Zevalin has the advantage that a one-time administra-
tion is needed compared with multiple cycles of chemotherapy. 
It is thought that the limited use of Zevalin has been, at least 
in part, due to lack of expertise and collaboration between 
oncologists and nuclear medicine physicians, poor patient 
access, concerns about radiation safety, and issues related to 
reimbursement.6,9 Bexxar (tositumomab) is a monoclonal 
mouse IgG2a anti-CD20 antibody to which a radioactive 
isotope (131I) is added for the purposes of targeted radiation 
therapy. Although treatment of similar patient groups with 
either Zevalin or Bexxar has yielded comparable results, there 
are no head-to-head comparisons of efficacy in randomized 
trials. Bexxar is less commonly used than Zevalin, possibly 
due to the fact that multiple visits are needed to determine 
the administered activity to maximize tumor response while 
minimizing toxicity. In addition, since the radioisotope label 
is 131I, this can result in thyroid exposure necessitating pre-
medication. The most important serious adverse effect of both 
Zevalin and Bexxar is severe prolonged cytopenia. Recently, 
there has been interest in designing randomized trials capa-
ble of defining the role of RIT within the cadre of available 
treatment, resolving reimbursement issues and improving 
access, at least in part through increased personnel training 
and collaboration.6,9 Today, RIT is typically integrated into 
the treatment of patients with relapsed or refractory follicular 
lymphoma or as consolidation after induction chemotherapy. 
RIT may also have a place in first-line or follow-up therapy for 
patients with B-cell NHL and in other hemopathies such as 
multiple myeloma.22
Future Prospects
There is a growing availability of novel TRT for the treatment 
of patients with cancer. One of the areas of active research 
involving TRT is the treatment of neuroendocrine disease. 
Neuroendocrine tumors constitute a heterogeneous group 
of diseases with limited treatment options. Peptide recep-
tor radionuclide therapy (PRRT) is a targeted therapy that 
uses peptides radiolabeled with either 90Y or 177Lu to deliver 
radiation to cancer cells that express somatostatin receptors. 
There has been considerable interest in PRRT because of 
the advantages inherent to targeted therapy at the molecular 
level that allows for minimal toxicity to nontargeted tissue. 
Indeed, PRRT has been shown to be well tolerated and can 
improve symptomatic control, progression-free survival, and 
overall survival for patients with metastatic and/or progres-
sive neuroendocrine malignancy.23,24 The principal short- and 
long-term adverse effects are renal and hematologic toxicity 
(myelodysplastic syndrome and acute leukemia), and there 
is ongoing work to establish strategies for minimizing this. 
Although not yet routinely available in North America, 
the experience in Europe dates from 1994 when PRRT 
was first used in Krenning’s group in Rotterdam. Indeed, 
the European Neuroendocrine Tumor Society Center of 
Excellence at Zentralklinik Bad Berka has more than 1,200 
patient visits and administers more than 500 cycles of PRRT 
every year.6 Research is also underway to establish the opti-
mal combination of TRT using 90Y- and/or 177Lu-labeled 
radiopharmaceuticals25 and nonradionuclide based therapy 
such as chemotherapy.26
It is also becoming increasingly possible to image sites 
of disease and then target these sites of disease using radio-
nuclide therapy. Over the last 10 years, there has been a 
proliferation of metabolic imaging agents and a host of new 
therapies for men with prostate cancer. TRT with Xofigo is 
becoming standard of care therapy for men with metastatic 
prostate cancer and research, regarding the role of Xofigo 
within the armamentarium of available prostate cancer 
therapy is ongoing. Several imaging studies have evaluated 
PET/CT for the detection of prostate cancer using agents that 
target fatty acid metabolism such as 11C-choline, 18F-choline, 
and 11C-acetate27–29 or amino acid transport such as anti-18F-
FACBC.30 Recent literature has suggested that radiotracers 
target the prostate-specific membrane antigen (PSMA) that 
could be used pre-therapy as a biomarker for differentiating 
aggressive from indolent disease.31 Radiopharmaceuticals tar-
geting PSMA could also provide the possibility of combining 
imaging and TRT in this patient population.32
There is ongoing research in the development of novel 
TRT and RIT, the approach for calculating the optimal 
amount of radiotracer to be administered, the possibility of 
developing new methods of radionuclide delivery, and the 
role of combination therapy.7,33 Indeed, TRT and RIT may 
be synergistic in combination with existing medical therapy 
and could augment the effectiveness of external beam radio-
therapy by increasing radiation dose to both macroscopic 
tumor and micrometastases.34 The benefit to patients would 
be more effective cancer treatment with reduced toxicity. It is 
also anticipated that there will be much research and devel-
opment activity in therapy-diagnostic pair radiopharma-
ceuticals (theragnostics) for a variety of cancers. Cancer is a 
heterogeneous family of disease and to develop a personalized 
approach to therapy, unbiased, accurate information will be 
needed on the role of radiopharmaceuticals within the spec-
trum of available therapy. In addition, the criteria necessary 
to chose the most appropriate patient and disease-specific tar-
geted oncologic therapy will need to be defined likely using 
biomarker/imaging information for patient stratification 
similarly to what has been done in other fields.35,36 Finally, 
research providing robust data on patient outcomes includ-
ing quality of life and impact on overall survival must be 
actively pursued.
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Conclusion
As our understanding of the molecular basis of disease 
continues to expand, TRT and RIT are becoming an area of 
significant interest and growth. There has long been an under-
standing of radionuclide chemistry and physical characteris-
tics of radionuclides; however, this is now being coupled with 
tumor-specific targeting agents such that imaging biomarkers 
of disease can be combined with radionuclide therapy. Based 
on our past experience with RIT for lymphoma, there is a 
need to foster collaboration between members of the health 
care team to promote easy access to radionuclide therapy 
and education about the benefits and risks for physicians and 
patients. Adoption of a practical approach to manufacturing 
and delivering radiopharmaceuticals, assessing patient eligi-
bility, ensuring posttherapy follow-up, and addressing reim-
bursement issues will be essential for success. There is so much 
that can be done with radionuclide therapy. The question that 
is likely to arise is not, can we do it but rather, where does it fit 
into our treatment strategy and how do we best implement it?
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